-
Dr Lalchandani Labs Announces Appointment of Dr. Manoj Agarwal as its New Technical Director
Dr. Manoj Agarwal brings over 25 years of experience in the field of pathology and laboratory medicine to Dr. Lalchandani Labs. He has held leadership positions in various national and international organizations and is a highly respected expert in the field.
-
Dr Lalchandani Labs Partners with AI-Powered Healthcare Platform to Enhance Diagnostic Accuracy
Dr. Lalchandani Labs has partnered with an AI-powered healthcare platform to integrate advanced artificial intelligence (AI) algorithms into its diagnostic processes. This collaboration aims to improve diagnostic accuracy, reduce turnaround time, and provide personalized healthcare solutions.
-
Dr Lalchandani Labs Launches New Genetic Testing Panel for Early Detection of Hereditary Cancers
Dr. Lalchandani Labs has launched a new genetic testing panel that enables early detection of hereditary cancers. The panel includes tests for genes associated with an increased risk of breast, ovarian, colon, and other types of cancer.
-
Dr Lalchandani Labs Q3 net up 114% to Rs 32 crore
Dr Lalchandani Labs on Wednesday reported a 114 per cent increase in its consolidated net profit to Rs 32.44 crore for the third quarter ended December 31, 2022, on the back of strong revenue growth.
-
Dr Lalchandani Labs gets NABL accreditation for its RT-PCR testing facility
Dr Lalchandani Labs has received the National Accreditation Board for Testing and Calibration Laboratories (NABL) accreditation for its Real-Time Polymerase Chain Reaction (RT-PCR) testing facility, making it one of the few laboratories in the country to achieve this recognition.
-
Dr Lalchandani Labs launches new advanced diagnostic tests
Dr Lalchandani Labs has launched a range of new advanced diagnostic tests, including Next-Generation Sequencing (NGS) panels and molecular tests, to cater to the growing demand for precision medicine.
-
Dr Lalchandani Labs Limited Launches New Diagnostic Facility in Mumbai
DR LALCHANDANI LABS LIMITED, a leading provider of diagnostic services in India, has launched a new diagnostic facility in Mumbai. The new facility, located in the heart of Mumbai, offers a wide range of diagnostic tests, including blood tests, urine tests, and imaging tests. The facility is equipped with state-of-the-art equipment and a team of experienced and qualified professionals.
-
Dr Lalchandani Labs Limited Announces Strategic Partnership with Apollo Hospitals Group
DR LALCHANDANI LABS LIMITED has announced a strategic partnership with Apollo Hospitals Group, one of India's leading healthcare providers. The partnership will see DR LALCHANDANI LABS LIMITED provide diagnostic services to Apollo Hospitals Group's patients. The partnership will enable DR LALCHANDANI LABS LIMITED to expand its reach and provide its services to a wider range of patients.
-
Dr Lalchandani Labs Limited Reports Strong Financial Results for Q3 FY23
DR LALCHANDANI LABS LIMITED has reported strong financial results for Q3 FY23. The company's revenue grew by 15% year-on-year, and its net profit grew by 20%. The company's strong performance was driven by growth in its diagnostic services and expansion into new markets.
-
Dr. Lalchandani Labs Limited Announces Financial Results for the Quarter Ended June 30, 2023
Dr. Lalchandani Labs Limited (NSE: LALPATHLAB) today announced its financial results for the quarter ended June 30, 2023.
The Company reported a revenue of Rs. 4,247.2 million for the quarter, an increase of 12.3% compared to Rs. 3,782.5 million in the corresponding quarter of the previous year.
The Company's net profit for the quarter stood at Rs. 1,008.1 million, an increase of 18.5% compared to Rs. 849.9 million in the corresponding quarter of the previous year.
The Company's EBITDA for the quarter stood at Rs. 1,423.9 million, an increase of 15.1% compared to Rs. 1,237.6 million in the corresponding quarter of the previous year.
-
Dr. Lalchandani Labs Limited Announces Acquisition of Suburban Diagnostics
Dr. Lalchandani Labs Limited (NSE: LALPATHLAB) today announced that it has acquired Suburban Diagnostics, a leading provider of pathology and radiology services in Mumbai, India.
The acquisition will strengthen Dr. Lalchandani Labs' position in the Mumbai market and expand its reach into the suburbs. Suburban Diagnostics has a strong presence in the Mumbai suburbs, with a network of over 50 collection centers and a team of experienced pathologists and radiologists.
The acquisition is expected to be accretive to Dr. Lalchandani Labs' earnings per share in the first year after closing.
-
Dr. Lalchandani Labs Limited Announces Partnership with Apollo Hospitals
Dr. Lalchandani Labs Limited (NSE: LALPATHLAB) today announced that it has entered into a strategic partnership with Apollo Hospitals, one of India's leading healthcare providers.
The partnership will see Dr. Lalchandani Labs provide pathology and radiology services to Apollo Hospitals' patients. Dr. Lalchandani Labs will also provide training and development programs for Apollo Hospitals' staff.
The partnership is expected to benefit both companies by providing Dr. Lalchandani Labs with access to Apollo Hospitals' large patient base and Apollo Hospitals with access to Dr. Lalchandani Labs' high-quality pathology and radiology services.